Honiton Hearing Centre
  • Youtube
  • Twitter
  • Facebook
  • Linkedin
  • Gplus
  • Home
  • Meet The Team
  • Services
    • Hearing Test
    • Hearing Protection
    • Hearing Aids
    • Tinnitus Control
    • Ear wax removal
    • Repairs
  • Testimonials
  • FAQ
  • News
  • Contact
  • Videos
    • What type of hearing aid do you need?
    • Ear Syringing Honiton Devon
    • Hopi Candles, Myth?
    • Hearing aid batteries Honiton
    • Hearing Test
    • How to change the wax guard
    • Ear Irrigation
    • Microsuction Ear wax Removal
  • Menu

Posts

Treatment of Ménière’s Disease and Vertigo with Intranasal Betahistine

June 22, 2020/in News /by admin

Treatment of Ménière’s Disease and Vertigo with Intranasal Betahistine

 

Treatment of Ménière’s Disease and Vertigo with Intranasal Betahistine

Auris MedicalAuris Medical Holding AG, a Swiss-based clinical-stage public company  (NASDAQ: EARS) dedicated to developing therapeutics in otolaryngology, has announced it will develop betahistine dihydrochloride in a spray formulation (with the product name AM-125) for the intranasal treatment of Ménière’s disease and vestibular vertigo. This represents the third clinical-stage development program to Auris Medical’s pipeline, and an expansion by the company into the field of vestibular disorders. Auris is also developing a drug for idiopathic sudden sensorineural hearing loss (ISSNHL, sudden hearing loss) and acute inner ear tinnitus.

“We are excited to add AM-125 to our development pipeline as it addresses important unmet medical needs in vestibular disorders and serves as a strategic fit with our existing projects,” said Auris Medical’s Founder, Chairman and CEO Thomas Meyer in a press statement. “While oral betahistine has been a mainstay treatment for Ménière’s disease and vestibular vertigo for many years and in many countries around the world, we expect the novel approach of intranasal delivery to offer significant additional benefits in terms of efficacy and tolerability.”

Auris Medical reports that it has entered into an agreement with Otifex Therapeutics Pty Ltd to purchase various assets related to intranasal betahistine, including preclinical and clinical data, as well as certain intellectual property rights. In a Phase 1 trial conducted by Otifex, intranasal betahistine showed good tolerance and a significantly higher bioavailability than reported for oral betahistine administration. Auris Medical plans to initiate a second Phase 1 trial in 2017.

“As our treatment options for vestibular disorders are currently very limited in the United States, I am pleased to see that betahistine will be developed as a treatment for patients here who are suffering from Ménière’s disease or vestibular vertigo,” said Lawrence R. Lustig, MD, Chair, Department of Otolaryngology at Columbia University Medical Center in the press release. “The compound has an established track record for safety, and the clinical experience suggests that it may help control or ease vertigo attacks in Ménière’s disease. It will be exciting to have a new treatment for this disabling condition.”

According to Auris Medical, Betahistine is a small molecule drug that acts as a partial histamine H1-receptor agonist and a H3-receptor antagonist. The compound has demonstrated increased cochlear, vestibular, and cerebral blood flow, vestibular compensation, and the ability to inhibit neuronal firing in the vestibular nuclei.

Oral betahistine is approved for the treatment of Ménière’s disease and vestibular vertigo in more than 80 countries worldwide, and has been reportedly prescribed more than 130 million patients. However, betahistine has not been approved for marketing in the United States for the past few decades.

The brand Serc (betahistine) was approved by the FDA in the early 1970s as vestibular suppressant for Ménière’s disease, but that approval was withdrawn after about 5 years. Primarily, the drug has had issues surrounding its clinical trials and subsequent proof of efficacy. Even though studies have shown betahistine effective against vertigo attacks, most of these studies have been criticized for design flaws. The Cochrane Library concluded in 2001 that “Most trials suggested a reduction of vertigo with betahistine and some suggested a reduction in tinnitus but all these effects may have been caused by bias in the methods. One trial with good methods showed no effect of betahistine on tinnitus compared with placebo in 35 patients. None of the trials showed any effect of betahistine on hearing loss. No serious adverse effects were found with betahistine.”

Update on Auris Medical Tinnitus Trials

Auris Medical also announced last week that it has resumed patient enrollment in the TACTT3 Phase 3 trial of Keyzilen® (AM-101) in acute and post-acute inner ear tinnitus. According to Reuters, the company experienced a set-back in August when the drug missed the main goals of a late-stage study by failing to meet the two co-primary effectiveness goals of statistically significant changes in tinnitus loudness and tinnitus burden compared to a placebo.

“Following the swift approval by regulatory agencies and ethics committees, we are pleased to resume enrollment under the amended protocol in the TACTT3 Phase 3 clinical trial of Keyzilen,” said Meyer. “We have applied key learnings from the TACTT2 trial that we believe substantially strengthen TACTT3’s probability of success, and we look forward to top-line results in early 2018.”

TACTT3, which is being conducted in Europe, is a randomized, double-blind, placebo-controlled Phase 3 trial in inner ear tinnitus following traumatic cochlear injury or otitis media. The trial previously enrolled more than 300 patients during the acute tinnitus stage (Stratum A) and approximately 330 patients during the post-acute tinnitus stage (Stratum B). As previously announced, the TACTT3 protocol was amended based on analysis of the TACTT2 Phase 3 trial outcomes. The amended protocol elevates the Tinnitus Functional Index score from a key secondary endpoint to an alternate primary efficacy endpoint, includes certain patient subgroups in confirmatory statistical testing, and increases the trial size with the enrollment of an additional 60 patients in each of Stratum A and B.

https://honiton-hearing.co.uk/wp-content/uploads/2020/06/Honiton-hearing-Treatment-of-Ménière’s-Disease-and-Vertigo-with-Intranasal-Betahistine-.jpg 528 620 admin https://honitonnew.leecurran.co.uk/wp-content/uploads/2018/03/honitonhearinglogo.png admin2020-06-22 11:54:132021-07-04 14:58:35Treatment of Ménière’s Disease and Vertigo with Intranasal Betahistine

Archive

  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018

Categories

  • Benefits of hearing aids
  • Depression
  • Depression and Hearing
  • Devon Ear syringing centre
  • Ear wax removal Devon
  • Ear wax removal Exeter
  • Earwax removal
  • Exeter hearing aids
  • Hearing aid batteries
  • Hearing aids
  • Hearing aids Devon
  • Hearing aids Exeter
  • Hearing loss
  • Hearing tests Devon
  • Honiton hearing aids
  • Hopi candles in Devon
  • News
  • Personal
  • Sound Watch
  • Streaming
  • Tinnitus
  • Uncategorized
  • Videos
  • Widex Moment hearing aids

Facebook

Instagram

Instagram has returned invalid data. Follow Me!

Areas that Honiton Hearing Centre services:

Exeter, Exmouth, Lyme Regis Bridport,Taunton, Wellington Tiverton, Honiton, Sidmouth, Ottery St Mary, Sidford, Axminster, Charmouth, Horton, Ilminster,Dunkeswell, East Budleigh, Sudbury, Branscombe, Beer, Seaton,Whimple, Clyst Honiton, Topsham, West Hill, Fairmile, Culmstock, Wiveliscombe, Dulverton, Bampton, Oakfordbridge, Morebath,Rackenford, Cove, Catworthy, Norton Fitzwarren, White Ball, Huntsham, Milverton, Bishops Lydeard, Chard, Beaminster, Crewkerne, South Petherton, Tytherleigh

Honiton Hearing Centre

12 New St, Honiton Devon
EX14 1EY

01404 47070 or 01884 255722

Please note: WE DO NOT SUPPLY GOODS OUTSIDE THE UK

Opening Hours

9:00-17:00 Mon-Fri
Closed on Saturday
Closed on Sunday

© Copyright - honitonhearing.co.uk - powered by leecurran.co.uk
  • Youtube
  • Twitter
  • Facebook
  • Linkedin
  • Gplus

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Honiton Hearing Centre
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Scroll to top